AbbVie Forms Auto-Immunology Partnership with HotSpot Therapeutics for US$335M

By Swati Sharan

Pharma Deals Review: Vol 2022 Issue 12 (Table of Contents)

Published: 21 Dec-2022

DOI: 10.3833/pdr.v2022.i12.2756     ISSN: 1756-7874

Section: Licensing



AbbVie has entered into a global collaboration and license agreement with HotSpot Therapeutics, in a deal worth up to US$335 M, to develop a small molecule interferon regulatory factor 5 (IRF5) inhibitor for the treatment of autoimmune diseases, leveraging the latter’s proprietary Smart Allostery™ drug discovery platform...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details